Effects of SEvoflurane on Gas Exchange and Inflammation in Patients With ARDS (SEGA Study)

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Numerous trials support the efficacy and safety of volatile anesthetic agents, namely inhalation of sevoflurane through dedicated devices, for the sedation of ICU patients. Several preclinical studies have shown that sevoflurane inhalation improves gas exchange and decreases pulmonary and systemic inflammation in experimental models of acute respiratory distress syndrome (ARDS).

The purpose of our prospective monocentric, randomized, controlled trial is to evaluate the effects of an early 48-hour sevoflurane inhalation on gas exchange and inflammation in patients with ARDS.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Clermont-Ferrand
• Treatments: Midazolam; Sevoflurane

Criteria

Inclusion Criteria:

• Patients with criteria for moderate to severe ARDS since less than 24 hours (

• Informed consent

Exclusion Criteria:

• Suspected or proven intracranial hypertension

• Midazolam, sevoflurane or cisatracurium allergy

• Medical history of malignant hyperthermia

• Severe liver failure

• Chemotherapy treatment in the last month

• Severe neutropenia (< 0.5 G/l)